Brief: Theseus Pharmaceuticals Gets U.S. FDA Orphan Drug Designation For THE-630
02/02/2022 13:06
Feb 2 (Reuters) - Theseus Pharmaceuticals Inc THRX.O :
* THESEUS PHARMACEUTICALS RECEIVES U.S. FDA ORPHAN DRUG
DESIGNATION FOR THE-630 FOR THE TREATMENT OF ADVANCED
GASTROINTESTINAL STROMAL TUMORS (GIST)
Source text for Eikon: ID:nPn1GnHwva
Further company coverage: THRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theseus Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Theseus Pharma rises as Concentra Biosciences agrees to take it private
Brief: Theseus Pharmaceuticals To Be Acquired by Concentra Biosciences
Brief: Theseus Pharmaceuticals Inc Says As Part Of A Reduction In Workforce, Co Terminated Employment Of Timothy P. Clackson, Co's CEO, Effective As Of Dec 7